Cel Sci (CVM) Other financing activities (2010 - 2026)

Cel Sci (CVM) posted Other financing activities of -$720.0 for Q1 2026, up 82.0% sequentially from -$4000.0 in Q4 2024.

Cel Sci (CVM) Other financing activities (2010 - 2026) Analysis & Trends

Cel Sci has reported Other financing activities for 14 years, with the latest figure at -$720.0 in Q1 2026.

Quarterly Other financing activities changed N/A year-over-year to -$720.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$720.0 (up 82.0% YoY) and the FY2022 annual result came in at $101225.0, down 98.31% from the prior year.
Other financing activities improved to -$720.0 in Q1 2026 per CVM's latest filing, from -$4000.0 in the prior quarter.
Over five years, Other financing activities peaked at $2.3 million in Q3 2023 and troughed at -$2.8 million in Q2 2023.
A 4-year average of -$2069.5 and a median of $6570.0 in 2022 frame the typical range for Other financing activities.
The widest YoY moves for Other financing activities: up 1052.02% in 2022, down 227.91% in 2022.
Over 4 years, Other financing activities stood at $447291.0 in 2022, then jumped by 423.81% to $2.3 million in 2023, then slumped by 100.17% to -$4000.0 in 2024, then jumped by 82.0% to -$720.0 in 2026.
According to Business Quant data, Other financing activities over the past three periods registered -$720.0, -$4000.0, and -$80620.0 for Q1 2026, Q4 2024, and Q3 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Cel Sci	2.12 Mn	-4.42 Mn	-

Download Data